Basic Information
Cholib
Regulatory Information
EMEA/H/C/002559
August 26, 2013
June 27, 2013
17
March 6, 2024
Company Information
Ireland
Damastown Industrial Park Mulhuddart Dublin 15 Dublin
VIATRIS HEALTHCARE
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Cholib is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Cholib. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Cholib. For practical information about using Cholib, patients should read the package leaflet or contact their doctor or pharmacist.